In today's Pharmaceutical Executive Daily, UCB announces a definitive agreement to acquire Candid Therapeutics for up to $2.2 ...

Deal terms include $2.0 billion upfront and up to $200 million milestone-based consideration, with closing anticipated in ...

Integrated operating frameworks are displacing fragmented vendor ecosystems, enabling faster launch readiness, omnichannel ...

Pharmaceutical Executive spoke with Aradigm Health CEO Will Shrank at the Asembia ASX26 Summit in Las Vegas. During the ...

DTP functions as an “affordability waterfall,” dynamically routing patients to MFN cash pricing, commercial insurance, or ...

In today's Pharmaceutical Executive Daily, we cover Sun Pharma's $11.75 billion acquisition of Organon and IMG Pharma's move ...

FDA cleared the first agent with an NMDA/sigma-1–based mechanism specifically for agitation in Alzheimer’s disease dementia, ...

In a conversation with Pharmaceutical Executive, Jeff Golfman, founder and president of Send 123, discusses how and why ...

Eligibility now includes ages 1–7 years with stage 2 T1D, defined by multiple diabetes autoantibodies plus dysglycemia ...

ODAC voted 7–1 (one abstention) that capivasertib plus abiraterone and ADT shows a favorable benefit–risk profile for ...

RNA rewards companies that can integrate biology, data science, manufacturing, and clinical development into a single ...

In today’s Pharmaceutical Executive Daily, Sanofi formally confirms its CEO leadership following a shareholder vote, US ...